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Ischemic preconditioning directly protects organs from
subsequent non-specific injuries. To test for systemic
protective effects kidneys from F-344 donor rats went
through a short warm ischemic time. Both, clamped and
contralateral unclamped kidneys were procured after either
a short (15 min) or long (24 h) reperfusion period and
transplanted into Lewis rats following a prolonged cold
ischemia. To test for transferable effects serum from
preconditioned rats was infused either into native donors or
recipients. Following a short reperfusion interval protective
effects were only evident in previously clamped grafts.
However, after a long reperfusion interval protective effects
were observed in previously clamped and contralateral
unclamped kidneys promoting improved survival, structure,
function and reduced inflammation. These effects were
not related to heme oxygenase-1 induction or neural
transmission as heme oxygenase-1 inhibition or denervation
prior to preconditioning did not affect organ protection.
These results show that renal ischemic preconditioning
is associated with time-dependent local and systemically
transferable protection.
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Ischemic preconditioning (IPC) as induced by one or more
cycles of brief warm ischemia and reperfusion, is associated
with local protection to subsequent ischemic injuries. The
beneficial effects of IPC were originally described in canine
hearts by Murry et al. in 1986. In this study, short periods of
coronary ischemia resulted in decreased infarction size, when
hearts were exposed to a subsequent prolonged ischemic
period.1 Since then, this phenomenon has been characterized
in various organs and tissues including liver, brain, small
intestine, lung, stomach, skeletal muscle, and kidney.2–6
Despite numerous animal studies demonstrating the bene-
ficial effects of IPC, its clinical application and efficacy
remains controversial as risks of an additional invasive mani-
pulation before the main intervention have to be considered.7
Various experimental models of IPC provided controver-
sial results. Although IPC had no significant effect in a large
animal model of warm or hypothermic renal ischemia/
reperfusion injury (IRI),8 IPC was effective in a dog model to
protect the liver against subsequent warm but not cold IRI.9
Glazier et al.10 reported on ischemic protection characterized
by marked reduction of neuronal necrosis following a brief
focal ischemia in the rat brain. Furthermore, IPC reduced
injury during prolonged cold ischemia in a rat model of
lung transplantation and protected intestinal grafts from IRI in
a rat intestinal transplantation model.11,12 Torras et al.13
demonstrated that a preconditioning interval of 15 min of
warm ischemia followed by 10 min of reperfusion protected
renal grafts from subsequent prolonged warm or cold
ischemia. Overall, these experimental studies demonstrate that
the efficacy of IPC strongly differs between large and small
animal models as well as between organs of the same species.
Clinically, Jenkins et al. showed for the first time that IPC
reduced myocardial injury in patients undergoing elective
coronary artery bypass surgery.14 Recently, a prospective
randomized study demonstrated the protective effects of IPC
in a clinical hepatic ischemia model.15 Although the relevance
of IPC in patients who are at risk of ischemia has been shown
in the human heart and liver, clinical studies of IPC in other
organs, for example the kidney or intestine, are still lacking.
To facilitate a clinical application, further research needs
to focus on potential mechanisms involved to support the
o r i g i n a l a r t i c l e http://www.kidney-international.org
& 2008 International Society of Nephrology
Received 15 May 2007; revised 13 February 2008; accepted 21 March
2008; published online 28 May 2008
Correspondence: Stefan G. Tullius, Division of Transplant Surgery, Brigham
and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston,
MA 02115, USA. E-mail: stullius@partners.org
4Both authors contributed equally to this work.
622 Kidney International (2008) 74, 622–630
development of pharmacological strategies mimicking the
effects of IPC as a substitute for an interventional procedure.
Different types of IPC have been classified. The ‘early’ or
‘classical’ IPC mediates protection immediately after the IPC
stimulus through several trigger substances such as adeno-
sine, bradykinin, norepinephrine, opioids, and reactive
oxygen species, all activating the intracellular signal cascade.
Components of this cascade include phoshatidylinositol-3-
kinase (PI3K), protein kinase C, protein tyrosine kinases,
mitogen-activated-protein kinases, the ATP-sensitive potas-
sium channel (KATP channel), and mitochondrial proteins as
end effectors.16 Early effects of IPC range from 2 to 3 h,
followed by a second protection period 24 h after the initial
stimulus, referred to as ‘late/delayed preconditioning’ or the
‘second window of protection’. In addition to the triggers
involved in ‘early’ precondtioning, nitric oxide (NO) seems
to play an important role in delayed preconditioning. The
subsequent signal cascade activates the transcriptional
regulator nuclear factor-kB causing an increased synthesis
of protective proteins such as inducible nitric oxide synthase
(iNOS), cyclooxygenase-2, and several heat shock proteins
like hsp70 and hsp32 (heme oxygenase-1/HO-1).16
Meanwhile, it is known that the benefit of IPC is not
limited to local effects, as protection is also observed in
remote tissues. Those systemic effects have been termed as
‘remote’ IPC or ‘preconditioning at a distance’.17,18 A role for
adenosine and the activation of a neurogenic pathway has
been postulated. Moreover, Przyklenk et al.19 demonstrated
that protective effects of IPC can be transferred to
nonpreconditioned animals via coronary effluent or even
whole blood transfusion, suggesting the involvement of
humoral mechanisms.
In kidney transplantation, IRI is associated with delayed
graft function and an increased alloresponse, thus promoting
the incidence of acute rejection episodes and late chronic
graft loss.20–22 Local IPC has been shown to ameliorate renal
IRI and to improve early graft function in several animal
models.8,13,23–25 However, effects of IPC on the long-term
outcome of renal allografts as well as systemically transferable
effects have not been described so far.
We addressed this topic in a rat kidney allotransplant
model using a preconditioning schedule of 10 min of warm
ischemia followed by short (15 min) and long (24 h)
reperfusion periods. To test systemic effects of IPC, we
followed long-term outcome of contralateral, nonmanipu-
lated kidney grafts (Figure 1). The role of HO-1 or local
neural transmission was examined in additional sets of
experiments. Finally, we transferred serum from precondi-
tioned animals collected 15 min and 24 h after clamping into
either native donors or recipients 24 h before transplantation
to test for transferable systemic effects.
RESULTS
Study design I
All recipients of clamped and contralateral nonmanipulated
grafts recovered 24 h after reperfusion survived the observa-
tion period of 12 weeks. In contrast, following a short-term
interval (15 min) between clamping and organ procurement
protective effects dominated in clamped kidneys (survival by
12 weeks: 86 vs 58%, P¼ 0.0243; Figure 2).
Allograft function after 12 weeks was significantly better
preserved in clamped grafts recovered after 15 min and in
nonmanipulated grafts procured after 24 h compared with
nonmanipulated grafts procured after a short time interval
(urinary protein (Uprot): 27±8 and 28±4 vs 69±15 mg/
24 h, P¼ 0.0558 and 0.0051, Figure 3a; creatinine clearance
(CrCl): 1.50±0.07 and 1.82±0.24 vs 1.12±0.17 ml/min,
P¼n.s. and 0.0332, Figure 3b). Structural deterioration and
inflammatory cell infiltration were reduced significantly in
nonmanipulated grafts procured after 24 h compared with
nonmanipulated grafts recovered after 15 min (glomerulo-
sclerosis: 21.9±1.5 vs 72.5±4.2%, P¼ 0.0001; arteriosclerosis:
2.2±0.1 vs 3.9±0.1, P¼ 0.0002; tubular atrophy: 2.3±0.2 vs
Recipient
LEW CsA 1.5 mg/kg x 10 days
Nx contralateral kidney of recipient at day 10
observation period: 12 weeks
Tx After 24 h of cold ischemia (4°C)
Group 2:
Group 1: a + b → organ recovery 15 min after reperfusion
a + b → organ recovery 24 h after reperfusion
b
a
Contralateral kidney
(unmanipulated
IPC: 10 min
Donor
F-344
Figure 1 | Study design I. Both (a) clamped and
(b) unmanipulated contralateral F-344 kidney grafts were
recovered either early (15 min) or late (24 h) after reperfusion
and transplanted into Lewis recipients following a prolonged
cold ischemia of 24 h.
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Figure 2 | Kaplan–Meyer survival analysis. Survival of Lewis
rats receiving either clamped or unmanipulated/contralateral
F-344 kidney transplants: grafts were recovered from F-344
donors either early (interval IPC–organ recovery: 15 min) or
late (interval IPC–organ recovery: 24 h) after IPC/reperfusion.
All recipients of clamped and contralateral nonmanipulated
grafts recovered 24 h after reperfusion survived the observation
period. In contrast, following a short-term interval between
clamping and organ procurement, protective effects were
predominantly observed in clamped kidneys (86 vs 58%
survival in recipients of contralateral kidneys; Po0.05).
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3.5±0.1, P¼ 0.0159; fibrosis: 1.6±0.2 vs 3.3±0.3, P¼ 0.0141;
cellular infiltration: 1.9±0.4 vs 3.3±0.2, n.s.; Figure 4a and b).
By day 3, numbers of intragraft ED1þ monocytes/
macrophages, CD4þ and CD8þ T cells, and MHC class II
expression were reduced in contralateral grafts recovered after
24 h, when compared with nonmanipulated grafts recovered
after 15 min (CD4: 135±15 vs 157±19 cells/field of view
(c/fv), n.s.; CD8: 40±7 vs 68±8 c/fv, P¼ 0.0519; ED1:
128±14 vs 156±9 c/fv, n.s.; MHC class II: 93±14 vs
154±15 c/fv; P¼ 0.045); however, these early differences
did not reach statistical significance. In contrast, significant
differences were observed by 12 weeks (nonmanipulated
grafts procured after 24 h vs 15 min interval; CD4þ : 121±17
vs 190±30 c/fv, n.s.; CD8þ : 74±3 vs 111±10 c/fv,
P¼ 0.009; ED1þ : 75±7 vs 137±21 c/fv, P¼ 0.0228; MHC
class II: 132±5 vs 209±27 c/fv; P¼ 0.0209; Figure 4c).
Moreover, at that time, inflammatory cell infiltrates in non-
manipulated grafts recovered after 24 h were even lower than
in clamped grafts procured after either a short- or long-term
interval (CD4þ : 121±17 vs 195±12 and 192±21 c/fv,
P¼ 0.0078 and 0.0365; ED1þ : 75±7 vs 107±6 and 109±
15 c/fv, P¼ 0.0096 and n.s.; MHC class II: 132±5 vs 196±13
and 227±23 c/fv; P¼ 0.0037 and 0.0092; Figure 4c).
Intrarenal HO-1 mRNA expression of clamped and
nonmanipulated organs evaluated in kidneys immediately
after the respective reperfusion period was comparable in all
groups (clamped grafts short and long-term interval, respec-
tively: 1.21±0.08 102/1.86±0.26 102 [2DCt] vs non-
manipulated short/long-term interval: 1.29±0.19 102/
1.62±0.65 102 [2DCt], n.s.).
Potential mediators of systemic effects in nonmanipulated
organs were tested in additional experiments following the
induction of IPC.
The expression of iNOS was more prominent in
nonmanipulated organs recovered 24 h following induction
of IPC (Figure 4d and e). Caspase-3 staining was absent in
nonmanipulated organs recovered after 24 h; however, it was
strongly positive when the period between clamping and
procurement was only 15 min (Figure 4f and g). Expression
of p38-mitogen-activated-protein kinase and hsp70 was low
and comparable in both groups at that time (not shown).
Study design II
We then tested the role of HO-1 blockade by pretreating
donors with ZnPP 24 h before IPC (Figure 5a,b). All
recipients of ZnPP-pretreated grafts survived the observation
period of 12 weeks. HO-1 inhibition did not prevent
protective systemic effects after IPC: renal function in
recipients of contalateral grafts from ZnPP-pretreated donors
procured after 24 h remained significantly improved com-
pared to nonmanipulated kidneys procured after a short-
term interval (Uprot: 13±2 mg/24 h vs 69±15 mg/24 h,
P¼ 0.0025, Figure 5c; CrCl: 1.42±0.06 vs 1.12±0.17 ml/min,
n.s., Figure 5d). Thus, HO-1 induction did not seem to be
critical for the observed systemic protective effects in
contralateral, nonmanipulated kidneys following IPC.
Study design III
In additional experiments, we tested the role of neural factors
on systemic effects of IPC (Figure 5a,b). Interestingly, protec-
tive effects were not influenced by the isolation of the kidney.
Structure and function of nonclamped isolated kidneys
contralateral to those subjected to IPC remained significantly
improved when procured after 24 h compared with nonisolated
contralateral grafts recovered after a short reperfusion period
(Uprot: 12±4 mg/24 h vs 69±15 mg/24 h, P¼ 0.0051; Figure
5c; CrCl: 1.55±0.23 vs 1.12±0.17 ml/min, n.s.; Figure 5d).
Study design IV
We then tested effects and kinetics of serum transfer
following IPC into secondary, nonmanipulated donor and
recipient animals (Figure 6a and b).
Serum transfer into Lewis recipients did not significantly
improve renal function when serum was transferred shortly
before transplantation. This observation was independent from
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Figure 3 | Graft function. (a) Urinary protein excretion
(Uprot mg/24 h) and (b) creatinine clearance (CrCl ml/min) of
clamped grafts recovered either early (filled triangle) or late
(open triangle) after IPC/reperfusion, and contralateral grafts
recovered either early (open square) or late (filled circle).
Allograft function had significantly improved in nonmanipulated
grafts following a 24 h interval (Uprot Po0.01 and CrCl
Po0.05 vs contralateral/15 min interval).
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the time of serum collection after IPC induction (Uprot, serum
collected shortly after reperfusion: 85±36 mg/24 h; serum
collected 24 h after reperfusion: 137±77 mg/24 h). Functional
deterioration by 6 months was comparable with control
transplants without serum transfer (Uprot, cold ischemia
control: 150±34 mg/24 h, n.s). In contrast, recipients receiving
serum 24 h before transplantation demonstrated improved
renal function long term, again not influenced by the time
interval between IPC and serum collection (serum collected
shortly after reperfusion: 34±11 mg/24 h; serum collected 24 h
after reperfusion: 50±22 mg/24 h, P¼ 0.0016 and P¼ 0.0085
vs cold ischemia control; Figure 7a).
Recipients of nonmanipulated F-344 kidneys that had
received serum from preconditioned F-344 donors 24 h before
transplantation demonstrated significantly improved function
(serum collected from preconditioned F-344 shortly after
reperfusion: 52±16 mg/24 h, serum collected 24 h after reper-
fusion: 50±22, P¼ 0.0135 and P¼ 0.0055 vs cold ischemia
control; Figure 7b), independent of the time of serum collection.
To exclude unspecific effects induced by the serum
transfer, an additional serum control group (recipients of
serum from nonmanipulated donors) was followed. Deterio-
ration of renal function after 24 h of cold ischemia was
advanced and comparable in animals receiving serum from
unmanipulated donors and those receiving no serum. More-
over, urinary proteinuria was significantly elevated compared
with animals that had received serum from donors with
previously clamped kidneys (Po0.05; Figure 7c, amendment).
DISCUSSION
In a rat kidney transplantation model, we were able to
show that protective effects of local IPC are systemically
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Figure 4 | Structural changes and cellular infiltration. Structural deterioration and cellular infiltration were significantly reduced
in contralateral grafts following a prolonged reperfusion period ((a): semiquantitative evaluation of structural changes; white
columns: contralateral kidney/interval IPC-organ recovery 15 min; black columns: contralateral kidney/interval 24 h; light gray: clamped
kidney/interval 15 min; dark gray: clamped kidney/interval 24 h; (b) representative hematoxylin-and-eosin stainings of contralateral grafts,
original magnification  200). Intragraft numbers of ED1þ monocytes/macrophages, CD8þ T cells and MHC class II expression were
significantly reduced in contralateral grafts after a prolonged reperfusion period ((c): cell counts (cells/field of view, original magnification
 400) evaluated by light microscopy following alkaline phosphatase-anti-alkaline phosphatase staining). (d–f) Expression of iNOS
and caspase-3. Representative immunohistological staining of iNOS and caspase-3 (original magnification  400) of nonmanipulated
organs recovered after a short or long period following clamping of the contralateral kidney: (d) organs recovered after a prolonged
reperfusion period showed an intense expression of iNOS (e) compared to organs recovered after a short reperfusion period. (f) Caspase-3
positive cells were not detected following a long reperfusion period. (g) In contrast, caspase-3 was strongly expressed intraglomerularly
in organs recovered 15 min after reperfusion.
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transferable in a time-dependent fashion. IPC reduced the
consequences of subsequent prolonged cold IRI and im-
proved long-term graft function. Neither HO-1 inhibition in
donors nor isolation of the contralateral kidney abolished
protective effects. Transferring serum of preconditioned
animals to either native donors or recipients was associated
with graft protection. However, these beneficial effects were
dependent on the time of serum transfer, but independent of
the time of serum collection.
Graft protection has been associated with HO-1 upregula-
tion earlier. In experimental models, HO-1 induction by heat
preconditioning or pharmacologically by Cobalt Protopor-
phyrin has been shown to protect against IRI and to preserve
graft function.26,27 However, in our study, protective effects
of IPC were not associated with an early HO-1 upregulation.
Furthermore, donor pretreatment with ZnPP, an inhibitor
of HO-1 induction, did not impact the protective effects of
remote preconditioning. Data obtained from a rat model of
reduced-size liver transplantation (ROLT) demonstrated that
HO-1 induction protected liver grafts from the consequences
of I/R and improved liver regeneration.28 In this study, HO
inhibition with ZnPP prevented the protective effects of
preconditioning. Hepatic injury and liver regeneration were
compromised following HO inhibition; however, markers of
oxidative stress as malondialdehyde, lipid hydroperoxides,
and H2O2 were comparable with control animals. HO-1
induction protected from early liver IRI in a rat model
ZnPP, i.p.
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Figure 5 | Study designs II and III. (a) Study design II: F-344 donors were pretreated with ZnPP (20 mg/kg) 24 h before IPC.
Contralateral grafts were recovered 24 h after reperfusion, kept on ice for 24 h and transplanted into Lewis recipients. (b) Study design III:
contralateral kidneys of F-344 donors were isolated from surrounding tissue, whereas the adventitia of renal artery and vein was
removed. Nonmanipulated kidneys were recovered 24 h after reperfusion, kept on ice for 24 h, and transplanted into Lewis recipients.
(c and d) Graft function, study designs II and III. Neither HO-1 inhibition by ZnPP-pretreatment (open triangle) nor isolation/denervation
(filled triangle) of contralateral grafts before IPC abolished systemic protective effects observed in contralateral grafts recovered
24 h after reperfusion (a: Uprot, mg/24 h; b: CrCl, ml/min).
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or 24 h before transplantation (Tx). Kidneys from native F-344
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of remote preconditioning following a brief limb ischemia.
HO-1 expression in hepatocytes was induced in the liver 4 h
after remote IPC and persisted for 24 h. Inhibition of HO-1
with ZnPP prevented protective effects in this model.29 Those
data are in sharp contrast to the results of our experiments.
It has been shown that the beneficial, dose-dependent
local effects of exogenous nitric oxide (NO) as achieved
by administration of NO releasers induce antioxidant and
antiapoptotic activities of hsp70 and HO-1.13,30 However,
data on renoprotective or cytotoxic effects of NO are still
conflicting. In a rat study of ischemic acute renal failure,
Nakajima et al.31 demonstrated that pre-ischemic treatment
with the NO donor FK409 was renoprotective, whereas post-
ischemic treatment aggravated IRI. Several authors reported
on the role of endogenous NO in IPC, although there is
no agreement on its benefits in renal function.13,23,32–36
Joo et al.37 have demonstrated in a mouse model that
‘delayed’ IPC (exposure to renal ischemia 24 h after IPC)
was associated with an increase of iNOS and hsp27 and
independent from hsp70 or HO-1 induction. These data are
consistent with our results showing an increased expression
of iNOS in organs recovered after a 24 h reperfusion period.
An inhibition of apoptotic processes by IPC has been
suggested by Lazou et al.38 Caspase-3 staining was absent in
our study in organs recovered 24 h after reperfusion;
however, it was strongly expressed in organs recovered early
after reperfusion.
In their elegant studies of remote preconditioning, Gho
et al.17 mentioned the involvement of a neurogenic pathway
in the mechanism of protection. Reperfusion was essential to
activate the neurogenic pathway, suggesting that substances
released systemically at the time of reperfusion stimulate
afferent neurofibers. Liem et al.39 reported that locally
released adenosine during small intestinal ischemia stimu-
lates afferent nerves in the mesenteric bed during early
reperfusion, thus initiating a neurogenic pathway resulting in
the activation of adenosine receptors in the target organ.
Whereas further studies confirmed the role of a neurogenic
pathway,40 other reports emphasized the relevance of NO in
IPC in the absence of a neurogenic involvement.41 Our own
data did not provide evidence for a neurogenic involvement.
Isolation of the kidney as well as removal of the adventitia did
not impact the protective effects of IPC. These findings are
supported by a recent report in an orthotopic porcine
transplant model suggesting that remote IPC leads to cardio-
protection via circulating factors in the absence of an intact
innervation of the target organ.42
Meanwhile, evidence has occured that humoral factors
participate in the mechanisms of remote IPC. Peripheral
blood proteomics following myocardial or renal IPC showed
a significant increase of several albumin fragments; however,
a known signaling function could not be associated.43 It has
been shown previously that cardioprotection by IPC can be
transferred to nonpreconditioned hearts via coronary effluent
or whole blood transfusion; however, the humoral trigger
remained unidentified.19 Further studies implicated the
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Figure 7 | Renal function following serum transfer. Serum
transfer from preconditioned F-344 rats to unmanipulated Lewis
recipients 24 h before transplantation significantly improved renal
function of native F-344 donor grafts by 6 months, independent of the
time of serum collection (a: Uprot following serum transfer to Lewis
recipients). In contrast, serum transfer at the time of transplantation
did not improve renal function. Serum transfer from preconditioned
F-344 rats to unmanipulated F-344 donors significantly improved graft
function in Lewis recipients by 6 months following transplantation,
again not influenced by the time of serum collection (b: Uprot
following serum transfer to native F-344 donors). Transfer of serum
from native animals did not contribute to protective effects: Urinary
protein in animals receiving native serum was comparable with control
animals without serum transfer and significantly elevated compared
with animals receiving serum from preconditioned donors (c: Po0.05).
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involvement of opioids, ATP-sensitive potassium channels,
and protein kinase C.19,44,45 The beneficial effects of remote
IPC have been shown in a recent clinical trial. Transient
upper limb ischemia in patients undergoing elective coronary
bypass was associated with reduced serum troponin-T release
in the perioperative period.46
Recently, Burne-Taney et al.47 presented an attractive,
novel mechanism suggesting immune cells as mediators of
renal IPC. Adoptive transfer of leukocytes isolated from the
spleens 5 days after renal IPC protected recipient nu/nu mice
from subsequent renal injury.
In our study, beneficial effects of preconditioning could be
transferred by serum components of the preconditioned
donor to either a second native donor or recipient before
transplantation. Whereas protective effects in the initial
experimental design were strongly dependent on the time of
organ recovery, protective effects mediated via serum transfer
were independent of the time of serum collection, but
strongly dependent on the time of serum transfer.
MATERIALS AND METHODS
Animals and kidney transplantation
Male inbred rats (12 weeks old, 220–275 g;Harlan Winkelmann,
Germany) were used throughout the experiments. Kidneys from
Fischer-344 rats (F-344, RT11v1) were transplanted into Lewis recipients
(Lew, RT11) using standard microsurgical techniques (anastomosis
time 25±5 min). Before organ recovery, grafts were perfused with
University of Wisconsin solution and preserved at 41C for 24 h. To
prevent acute rejection episodes, recipients were treated with a low dose
of cyclosporine A (1.5 mg/kg 10 d). Nephrectomy of the contralateral
kidney in Lewis recipients was performed on day 10.
Animals were cared for according to the NIH guidelines for
laboratory animal care. Experiments were performed with the
permission of the local authorities.
Study design
Study design I. Warm ischemia was induced in a single kidney
of F-344 donors by clamping both renal artery and vein for 10 min.
The contralateral kidney remained untreated. Both clamped (a) and
nonmanipulated kidneys (b) were recovered either early (15 min,
group 1) or late (24 h, group 2) after reperfusion and transplanted
into Lewis recipients following a prolonged cold (41C) ischemic
time of 24 h (Figure 1, Table 1). Animals were followed for 12 weeks.
Renal function was analyzed serially. Structural changes were exa-
mined at the end of the observation period. Immunohistochemical
analysis of inflammatory cell infiltrates and MHC class II expression
were performed 3 days and 12 weeks after transplantation.
In an additional series, both clamped and nonmanipulated
contralateral grafts were recovered immediately after a short
(15 min) or prolonged reperfusion period (24 h; n¼ 5/group) to
evaluate potential mediators of IPC. Frozen sections were stained for
p38-mitogen-activated-protein kinase, iNOS, hsp-70, and caspase-3
by immunohistology; HO-1 expression was examined by real-time
reverse transcriptase-PCR.
Study design II. To investigate the role of HO-1 induction
on systemic effects of IPC, donors were pretreated with ZnPP
to inhibit HO-1 induction. ZnPP (Protoporphyrin IX zinc (II),
Sigma-Aldrich, Schnelldorf, Germany) was administered i.p. at a
dose of 20 mg/kg to F-344 donors 24 h before IPC (n¼ 5).
Contralateral nonmanipulated kidneys were procured 24 h after
reperfusion, kept on ice for 24 h, and then transplanted into Lewis
recipients (Figure 5a). Animals were followed for 12 weeks. Survival,
graft function, and structural changes were examined as described.
Results were compared with contralateral grafts procured 15 min or
24 h after reperfusion in the absence of ZnPP pretreatment.
Study design III. In addition, we investigated the role of neural
factors as transmitters of systemic consequences following IPC.
Twenty-four hours before IPC, contralateral kidneys of F-344
donors were isolated from surrounding tissue, whereas the adven-
titia of renal artery and vein was removed (n¼ 5). Twenty-four
hours after reperfusion, nonmanipulated kidneys were recovered
and grafted into Lewis recipients following a 24 h period on ice
(Figure 5b). Results were compared with nonisolated contralateral
grafts procured 15 min or 24 h after reperfusion.
Study design IV. This set of experiments was designed to test
for transferable systemic effects of IPC and kinetics in donor and
recipient animals.
Group 1: serum of preconditioned F-344 rats (1st F-344) was
collected either 15 min or 24 h after clamping of a single kidney and
transferred (i.p.) to Lewis recipients either at the time of or 24 h
before transplantation (n¼ 6/group). Kidneys from native F-344
donors (2nd F-344) were subsequently grafted following a cold
ischemia of 24 h into Lew recipients (Figure 6a).
Group 2: to test the effects of serum transfer into donor animals,
similar experiments were designed; however, serum was transferred
to native F-344 donors (2nd F-344; n¼ 6/group) (Figure 6b).
Both Lewis recipients of native F-344 kidneys following a
prolonged cold ischemia without serum transfer (cold ischemia
control: observation period 6 months; n¼ 6) and transplant
recipients (cold ischemia 24 h) receiving serum from nonmanipu-
lated donors 24 h before transplantation (serum control: observation
period 3 months; n¼ 6, amendment) served as controls. Renal
function was followed at monthly intervals.
Renal function
Serum and urine samples were collected in all groups at sequential
time intervals. Creatinine clearance (CrCl, ml/min) was tested
at monthly intervals and calculated as: urine creatinine (mg/ml) 
urine volume (ml)/serum creatinine (mg/ml)  time of urine
collection (min).
Proteinuria as the most sensitive parameter for chronic renal
allograft nephropathy in our transplant model was evaluated serially.
Uprot (mg/24 h) was assessed by turbidimetry and benzethonium
chloride (C27H42NO2Cl) precipitation.
Histology
Structural changes in allografts were evaluated at the end of the
respective observation period. Specimens were fixed in 4% buffered
Table 1 | Groups of study design I
Groups
Number (n)/
group
Clamped kidneys recovered 15 min after reperfusion 7
Clamped kidneys recovered 24 h after reperfusion 6
Nonmanipulated contralateral kidneys recovered 15 min
after reperfusion
12
Nonmanipulated contralateral kidneys recovered 24 h
after reperfusion
10
Number (n) of animals in the respective groups of the initial experiment (study
design I).
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formalin, paraffin embedded, stained with hematoxylin and eosin
and assessed by light microscopy. To determine the extent of
glomerulosclerosis, the number of glomeruli per kidney section was
counted and the ratio expressed as a percentage of affected-to-
normal glomeruli. The extent of arteriosclerosis, inflammatory cell
infiltrates, tubular atrophy, and interstitial fibrosis was quantified on
a 0 to þ 4 scale (þ 4¼ greatest structural deterioration/420 fields
of view per section were evaluated at  200).
Immunohistology
Representative graft segments were snap-frozen in liquid nitrogen
and analyzed for inflammatory cell infiltrates and expression of
MHC class II using the alkaline phosphatase-anti-alkaline phos-
phatase technique. Four-micron-thick cryostat sections were stained
with mouse monoclonal antibodies (Serotec, AbD Serotec,
Du¨sseldorf, Germany) directed against rat CD4þ (W3/25) and
CD8þ T cells (OX8), monocytes/macrophages (ED1), and MHC
class II (OX3). Subsequently, sections were stained with rabbit anti-
mouse IgG, followed by the incubation with the alkaline
phosphatase-anti-alkaline phosphatase/horseradish peroxidase com-
plex. Sections were counterstained with hematoxylin. Slides were
evaluated with light microscopy ( 400). Positive cells were counted
and expressed as mean±s.e.m. of cells/field of view (c/fv); 420 fv/
section were evaluated.
Additional graft sections from organs recovered following IPC
were stained with mouse monoclonal antibody directed against
hsp70 (BRM-22; Sigma-Aldrich) and mitogen-activated-protein
kinase-p38 (clone 30; BD Biosciences Pharmingen, Heidelberg,
Germany), rabbit monoclonal antibody anti-caspase-3 (Y83-77;
Epitomics/Biomol, Hamburg, Germany), and polyclonal rabbit
anti-iNOS (inducible nitric oxide synthase; Dianova, Hamburg,
Germany) antibody.
Reverse transcriptase PCR
Intragraft gene expression of HO-1 in organs recovered following
IPC was assessed by real-time reverse transcriptase-PCR. To measure
HO-1 mRNA levels, the expression of the gene transcript was
analyzed by real-time reverse transcriptase-PCR using the ABI
PRISM 7700 Sequence Detection System (TaqMan, Perkin
Elmer Biosystems, Weiterstadt, Germany). The cycle number at
which the amplification plot crossed the assigned threshold was
defined as the threshold cycle (Ct). For quantification, Ct was
correlated to the constant expression of a housekeeping gene and
then defined as [D]Ct¼Ct (gene of interest)Ct (housekeeping
gene); values are plotted as 2DCt. Primers and probes were designed
and validated at the Institute of Medical Immunology, Charite´,
Berlin.
Statistics
Data were expressed as mean±standard error of mean (s.e.m.).
Multiple group comparisons were performed using analysis of
variance and Bonferroni post test. For single comparisons (two
selected groups of interest), normally distributed data were analyzed
using unpaired, two-tailed t-test, whereas non-normally distributed
data were evaluated by nonparametric Mann–Whitney U-test.
Survival rates were assessed by Kaplan–Meier and compared with
Logrank test. Differences were considered significant at Po0.05.
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